19 August 2026 in Bioengineering & Translational Medicine
Neutrophils are the primary immune cell type present within the blood and the first to arrive at sites of inflammation. As such, neutrophils set the stage for how the inflammatory response progresses and resolves. In some cases of non‐resolving inflammation, excessive neutrophil accumulation can cause tissue damage. Accordingly, maintaining tight control over their recruitment and behavior at sites of inflammation is paramount. Historically, corticosteroids have been used to modulate inflammation, but they are associated with systemic side effects that have limited their use. Here, we developed an iron‐dexamethasone nanoparticle (DexOx NP) therapeutic that modulates neutrophil behavior and reroutes neutrophils away from sites of inflammation. DexOx NPs inhibit neutrophil activation, as indicated by prevention of L‐selectin shedding and reduced neutrophil extracellular trap formation. Furthermore, treatment with DexOx NPs in a murine acute lung injury model significantly reduced the total number of neutrophils in the bronchoalveolar lavage fluid while avoiding the side effects of systemic soluble dexamethasone phosphate delivery. Thus, DexOx NPs represent a new option to control non‐resolving neutrophilic inflammation.
24 November 2025 in bioRxiv
Joint inflammation is a hallmark of post-traumatic osteoarthritis (PTOA) progression and a recognized driver of articular destruction and symptoms. Despite its known pathological role, inflammation has not been successfully targeted to treat PTOA. With the hypothesis that blocking the acute influx of systemically-derived immune cells can mitigate injury-induced inflammation and downstream PTOA disease severity, we targeted immune cell recruitment via systemically-administered poly salicylic acid (PolySA) particles. This formulation targets immune cells in circulation, namely neutrophils and monocytes, to inhibit their vascular extravasation into injured tissue. Employing a murine joint injury model, we show that PolySA particles reduced neutrophil and monocyte recruitment to the synovium by >50% when administered acutely after injury. Sex-specific therapeutic effects of PolySA emerged 7d post-ACLR, whereby female knee joints exhibited increased cathepsin activity and alleviation of knee hyperalgesia. Despite also observing reduced immune cell recruitment in male mice treated with PolySA, therapeutic effects were entirely absent in males. RNAseq of female synovium revealed a transcriptomic signature indicative of accelerated immune resolution and matrix remodeling in PolySA-treated female mice. Analyses at a timepoint of established disease showed that PolySA-treated female mice exhibited sustained pain alleviation, reduced osteophyte formation, and decreased histopathological PTOA and synovitis severity scores. Together, these findings indicate that blocking acutely-recruited immune cells to the local joint microenvironment via systemic PolySA particle treatment is a promising therapeutic for PTOA prevention by reprogramming early injury-induced inflammation.